Skip to main content
main-content

12.09.2022 | Original Article

Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study

verfasst von: Shiwei Wang, Yu Wang, Li Zhu, Liang He, Mutian Lv, Hao Zhang, Haoyu Wang, Fan Zhang, Yaxin Lai, Yushu Li, Zhongyan Shan, Weiping Teng

Erschienen in: Endocrine

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to evaluate the effects of thyroid-stimulating hormone (TSH) suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in differentiated thyroid cancer (DTC) patients after postoperative 1–2 years in Northeast China.

Methods

Five male, sixteen premenopausal, and eight postmenopausal female DTC patients receiving TSH suppressive therapy after thyroidectomy were enrolled. Patients were matched with healthy controls in a ratio of 1:2. All participants completed postoperative 1-year follow-up, and postmenopausal women completed 2-year follow-up. We measured BMD of the lumbar spine (LS), femoral neck (FN), and total hip (TH) using dual-energy X-ray absorptiometry (DXA). Bone formation marker P1NP and bone resorption marker β-CTX were also evaluated. Fracture risks were assessed by FRAX.

Results

There was no difference in BMD and BTMs between DTC patients and controls in the male group at 1-year follow-up. In the premenopausal women, the baseline P1NP was significantly lower in DTC patients than in the controls. The LS-BMD, FN-BMD, and TH-BMD in DTC patients were all higher than those in controls at 1-year follow-up. The difference in FN-BMD was not significant after adjusting for baseline P1NP. In the postmenopausal women, no differences in BMD and BTMs were observed between DTC patients and controls at the 1-year and 2-year follow-up.

Conclusion

Our study indicated that postoperative 1-year TSH suppressive therapy did not show detrimental effects on BMD and BTMs in men, premenopausal, and postmenopausal DTC patients. The 2-year postoperative TSH suppressive therapy did not lead to additional loss of bone mass in postmenopausal DTC patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat M.E. Cabanillas, D.G. McFadden, C. Durante, Thyroid cancer. Lancet 388, 2783–2795 (2016) CrossRef M.E. Cabanillas, D.G. McFadden, C. Durante, Thyroid cancer. Lancet 388, 2783–2795 (2016) CrossRef
2.
Zurück zum Zitat D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009) CrossRef D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009) CrossRef
3.
Zurück zum Zitat M. Cellini, M. Rotondi, M.L. Tanda, E. Piantanida, L. Chiovato, P. Beck-Peccoz, A. Lania, G. Mazziotti, Skeletal health in patients with differentiated thyroid carcinoma. J. Endocrinol. Invest 44, 431–442 (2021) CrossRef M. Cellini, M. Rotondi, M.L. Tanda, E. Piantanida, L. Chiovato, P. Beck-Peccoz, A. Lania, G. Mazziotti, Skeletal health in patients with differentiated thyroid carcinoma. J. Endocrinol. Invest 44, 431–442 (2021) CrossRef
4.
Zurück zum Zitat M.R. Blum, D.C. Bauer, T.H. Collet, H.A. Fink, A.R. Cappola, B.R. da Costa, C.D. Wirth, R.P. Peeters, B.O. Åsvold, W.P. den Elzen, R.N. Luben, M. Imaizumi, A.P. Bremner, A. Gogakos, R. Eastell, P.M. Kearney, E.S. Strotmeyer, E.R. Wallace, M. Hoff, G. Ceresini, F. Rivadeneira, A.G. Uitterlinden, D.J. Stott, R.G. Westendorp, K.T. Khaw, A. Langhammer, L. Ferrucci, J. Gussekloo, G.R. Williams, J.P. Walsh, P. Jüni, D. Aujesky, N. Rodondi, Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313, 2055–2065 (2015) CrossRef M.R. Blum, D.C. Bauer, T.H. Collet, H.A. Fink, A.R. Cappola, B.R. da Costa, C.D. Wirth, R.P. Peeters, B.O. Åsvold, W.P. den Elzen, R.N. Luben, M. Imaizumi, A.P. Bremner, A. Gogakos, R. Eastell, P.M. Kearney, E.S. Strotmeyer, E.R. Wallace, M. Hoff, G. Ceresini, F. Rivadeneira, A.G. Uitterlinden, D.J. Stott, R.G. Westendorp, K.T. Khaw, A. Langhammer, L. Ferrucci, J. Gussekloo, G.R. Williams, J.P. Walsh, P. Jüni, D. Aujesky, N. Rodondi, Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313, 2055–2065 (2015) CrossRef
5.
Zurück zum Zitat I. Karner, Z. Hrgović, S. Sijanović, D. Buković, A. Klobucar, K.H. Usadel, W.J. Fassbender, Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine. Eur. J. Med. Res 10, 480–488 (2005) PubMed I. Karner, Z. Hrgović, S. Sijanović, D. Buković, A. Klobucar, K.H. Usadel, W.J. Fassbender, Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine. Eur. J. Med. Res 10, 480–488 (2005) PubMed
6.
Zurück zum Zitat I. Sugitani, Y. Fujimoto, Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 150, 1250–1257 (2011) CrossRef I. Sugitani, Y. Fujimoto, Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 150, 1250–1257 (2011) CrossRef
7.
Zurück zum Zitat R. Schneider, M. Schneider, C. Reiners, P. Schneider, Effects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort study. J. Clin. Endocrinol. Metab. 97, 3926–3934 (2012) CrossRef R. Schneider, M. Schneider, C. Reiners, P. Schneider, Effects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort study. J. Clin. Endocrinol. Metab. 97, 3926–3934 (2012) CrossRef
8.
Zurück zum Zitat E.E. Mazokopakis, I.K. Starakis, M.G. Papadomanolaki, A.G. Batistakis, J.A. Papadakis, Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy. Curr. Med. Res. Opin. 22, 1369–1373 (2006) CrossRef E.E. Mazokopakis, I.K. Starakis, M.G. Papadomanolaki, A.G. Batistakis, J.A. Papadakis, Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy. Curr. Med. Res. Opin. 22, 1369–1373 (2006) CrossRef
9.
Zurück zum Zitat E. Jódar, M. Begoña López, L. García, D. Rigopoulou, G. Martínez, F. Hawkins, Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass. Osteoporos. Int 8, 311–316 (1998) CrossRef E. Jódar, M. Begoña López, L. García, D. Rigopoulou, G. Martínez, F. Hawkins, Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass. Osteoporos. Int 8, 311–316 (1998) CrossRef
10.
Zurück zum Zitat P. Zhang, H. Xi, R. Yan, Effects of thyrotropin suppression on lumbar bone mineral density in postmenopausal women with differentiated thyroid carcinoma. Onco Targets Ther. 11, 6687–6692 (2018) CrossRef P. Zhang, H. Xi, R. Yan, Effects of thyrotropin suppression on lumbar bone mineral density in postmenopausal women with differentiated thyroid carcinoma. Onco Targets Ther. 11, 6687–6692 (2018) CrossRef
11.
Zurück zum Zitat D. Bin-Hong, D. Fu-Man, L. Yu, W. Xu-Ping, B. Bing-Feng, Effects of levothyroxine therapy on bone mineral density and bone turnover markers in premenopausal women with thyroid cancer after thyroidectomy. Endokrynol. Pol. 71, 15–20 (2020) CrossRef D. Bin-Hong, D. Fu-Man, L. Yu, W. Xu-Ping, B. Bing-Feng, Effects of levothyroxine therapy on bone mineral density and bone turnover markers in premenopausal women with thyroid cancer after thyroidectomy. Endokrynol. Pol. 71, 15–20 (2020) CrossRef
12.
Zurück zum Zitat Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis (2017). Chinese J Osteoporosis Mineral Res 25, 281–309 (2019). Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis (2017). Chinese J Osteoporosis Mineral Res 25, 281–309 (2019).
13.
Zurück zum Zitat N.J. McGriff, G. Csako, L. Gourgiotis, C.G. Lori, F. Pucino, N.J. Sarlis, Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann. Med 34, 554–564 (2002) CrossRef N.J. McGriff, G. Csako, L. Gourgiotis, C.G. Lori, F. Pucino, N.J. Sarlis, Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann. Med 34, 554–564 (2002) CrossRef
14.
Zurück zum Zitat J.A. Kanis, F. Borgstrom, C. De Laet, H. Johansson, O. Johnell, B. Jonsson, A. Oden, N. Zethraeus, B. Pfleger, N. Khaltaev, Assessment of fracture risk. Osteoporos. Int 16, 581–589 (2005) CrossRef J.A. Kanis, F. Borgstrom, C. De Laet, H. Johansson, O. Johnell, B. Jonsson, A. Oden, N. Zethraeus, B. Pfleger, N. Khaltaev, Assessment of fracture risk. Osteoporos. Int 16, 581–589 (2005) CrossRef
15.
Zurück zum Zitat R. Eastell, P. Szulc, Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 5, 908–923 (2017) CrossRef R. Eastell, P. Szulc, Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 5, 908–923 (2017) CrossRef
16.
Zurück zum Zitat C.Y. Guo, A.P. Weetman, R. Eastell, Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin. Endocrinol. (Oxf.) 46, 301–307 (1997) CrossRef C.Y. Guo, A.P. Weetman, R. Eastell, Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin. Endocrinol. (Oxf.) 46, 301–307 (1997) CrossRef
17.
Zurück zum Zitat E.J. Ku, W.S. Yoo, E.K. Lee, H.Y. Ahn, S.H. Woo, J.H. Hong, H.K. Chung, J.W. Park, Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 106, 3655–3667 (2021) CrossRef E.J. Ku, W.S. Yoo, E.K. Lee, H.Y. Ahn, S.H. Woo, J.H. Hong, H.K. Chung, J.W. Park, Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 106, 3655–3667 (2021) CrossRef
18.
Zurück zum Zitat J.H. Moon, K.M. Kim, T.J. Oh, S.H. Choi, S. Lim, Y.J. Park, D.J. Park, H.C. Jang, The effect of TSH suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 102, 78–85 (2017) PubMed J.H. Moon, K.M. Kim, T.J. Oh, S.H. Choi, S. Lim, Y.J. Park, D.J. Park, H.C. Jang, The effect of TSH suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 102, 78–85 (2017) PubMed
19.
Zurück zum Zitat B.H. Yoon, Y. Lee, H.J. Oh, S.H. Kim, Y.K. Lee, Influence of thyroid-stimulating hormone suppression therapy on bone mineral density in patients with differentiated thyroid cancer: a meta-analysis. J. Bone Metab. 26, 51–60 (2019) CrossRef B.H. Yoon, Y. Lee, H.J. Oh, S.H. Kim, Y.K. Lee, Influence of thyroid-stimulating hormone suppression therapy on bone mineral density in patients with differentiated thyroid cancer: a meta-analysis. J. Bone Metab. 26, 51–60 (2019) CrossRef
20.
Zurück zum Zitat R.M.C. Olímpio, F.C.F. Moretto, M.T. De Sibio, M. de Oliveira, L.S. Mathias, B.M. Gonçalves, I.C. Deprá, H.P. Tilli, B.M. Rodrigues, P.P. Saraiva, D.A. Maria, C.R. Nogueira, The importance of estrogen for bone protection in experimental hyperthyroidism in human osteoblasts. Life Sci. 231, 116556 (2019) CrossRef R.M.C. Olímpio, F.C.F. Moretto, M.T. De Sibio, M. de Oliveira, L.S. Mathias, B.M. Gonçalves, I.C. Deprá, H.P. Tilli, B.M. Rodrigues, P.P. Saraiva, D.A. Maria, C.R. Nogueira, The importance of estrogen for bone protection in experimental hyperthyroidism in human osteoblasts. Life Sci. 231, 116556 (2019) CrossRef
21.
Zurück zum Zitat V. Sozer, H. Uzun, I. Guner, S. Aydin, R. Yucel, Y. Karter, C. Simsek, S. Kaya, G. Yigit, G. Simsek, Bone metabolism in ovariectomized rats with induced hyperthyroidism: the effect of estrogen replacement. Chin. J. Physiol. 49, 335–341 (2006) PubMed V. Sozer, H. Uzun, I. Guner, S. Aydin, R. Yucel, Y. Karter, C. Simsek, S. Kaya, G. Yigit, G. Simsek, Bone metabolism in ovariectomized rats with induced hyperthyroidism: the effect of estrogen replacement. Chin. J. Physiol. 49, 335–341 (2006) PubMed
22.
Zurück zum Zitat A. Brancatella, C. Marcocci, TSH suppressive therapy and bone. Endocr. Connect 9, R158–r172 (2020) CrossRef A. Brancatella, C. Marcocci, TSH suppressive therapy and bone. Endocr. Connect 9, R158–r172 (2020) CrossRef
23.
Zurück zum Zitat B.É.C.A. Sousa, B.C. Silva, T. de Oliveira Guidotti, M.C. Pires, M.M.S. Soares, A.M. Kakehasi, Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy. J. Endocrinol. Invest 44, 2295–2305 (2021) CrossRef B.É.C.A. Sousa, B.C. Silva, T. de Oliveira Guidotti, M.C. Pires, M.M.S. Soares, A.M. Kakehasi, Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy. J. Endocrinol. Invest 44, 2295–2305 (2021) CrossRef
24.
Zurück zum Zitat L. Vera, S. Gay, C. Campomenosi, S. Paolino, G. Pera, E. Monti, L. Mortara, B. Seriolo, M. Giusti, Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy. Endokrynol. Pol. 67, 350–358 (2016) PubMed L. Vera, S. Gay, C. Campomenosi, S. Paolino, G. Pera, E. Monti, L. Mortara, B. Seriolo, M. Giusti, Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy. Endokrynol. Pol. 67, 350–358 (2016) PubMed
25.
Zurück zum Zitat D.W. Shin, B. Suh, H. Lim, J.M. Yun, S.O. Song, Y. Park, J-shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients: a retrospective cohort study. J. Bone Min. Res 33, 1037–1043 (2018) CrossRef D.W. Shin, B. Suh, H. Lim, J.M. Yun, S.O. Song, Y. Park, J-shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients: a retrospective cohort study. J. Bone Min. Res 33, 1037–1043 (2018) CrossRef
26.
Zurück zum Zitat S.Y. Lin, C.L. Lin, H.T. Chen, C.H. Kao, Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study. Curr. Med Res Opin. 34, 805–812 (2018) CrossRef S.Y. Lin, C.L. Lin, H.T. Chen, C.H. Kao, Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study. Curr. Med Res Opin. 34, 805–812 (2018) CrossRef
27.
Zurück zum Zitat X. Fu, X. Zhao, H. Lu, F. Jiang, X. Ma, S. Zhu, Association between sleep duration and bone mineral density in Chinese women. Bone 49, 1062–1066 (2011) CrossRef X. Fu, X. Zhao, H. Lu, F. Jiang, X. Ma, S. Zhu, Association between sleep duration and bone mineral density in Chinese women. Bone 49, 1062–1066 (2011) CrossRef
28.
Zurück zum Zitat F. Varga, M. Rumpler, R. Zoehrer, C. Turecek, S. Spitzer, R. Thaler, E.P. Paschalis, K. Klaushofer, T3 affects expression of collagen I and collagen cross-linking in bone cell cultures. Biochem Biophys. Res Commun. 402, 180–185 (2010) CrossRef F. Varga, M. Rumpler, R. Zoehrer, C. Turecek, S. Spitzer, R. Thaler, E.P. Paschalis, K. Klaushofer, T3 affects expression of collagen I and collagen cross-linking in bone cell cultures. Biochem Biophys. Res Commun. 402, 180–185 (2010) CrossRef
29.
Zurück zum Zitat J.A. Waung, J.H. Bassett, G.R. Williams, Thyroid hormone metabolism in skeletal development and adult bone maintenance. Trends Endocrinol. Metab. 23, 155–162 (2012) CrossRef J.A. Waung, J.H. Bassett, G.R. Williams, Thyroid hormone metabolism in skeletal development and adult bone maintenance. Trends Endocrinol. Metab. 23, 155–162 (2012) CrossRef
30.
Zurück zum Zitat A. Gürlek, O. Gedik, Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 9, 539–543 (1999) CrossRef A. Gürlek, O. Gedik, Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 9, 539–543 (1999) CrossRef
31.
Zurück zum Zitat S. Tournis, J.D. Antoniou, C.G. Liakou, J. Christodoulou, E. Papakitsou, A. Galanos, K. Makris, H. Marketos, S. Nikopoulou, I. Tzavara, I.K. Triantafyllopoulos, I. Dontas, N. Papaioannou, G.P. Lyritis, M. Alevizaki, Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression. Clin. Endocrinol. (Oxf.) 82, 197–204 (2015) CrossRef S. Tournis, J.D. Antoniou, C.G. Liakou, J. Christodoulou, E. Papakitsou, A. Galanos, K. Makris, H. Marketos, S. Nikopoulou, I. Tzavara, I.K. Triantafyllopoulos, I. Dontas, N. Papaioannou, G.P. Lyritis, M. Alevizaki, Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression. Clin. Endocrinol. (Oxf.) 82, 197–204 (2015) CrossRef
32.
Zurück zum Zitat A.C. Heijckmann, M.S. Huijberts, P. Geusens, J. de Vries, P.P. Menheere, B.H. Wolffenbuttel, Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur. J. Endocrinol. 153, 23–29 (2005) CrossRef A.C. Heijckmann, M.S. Huijberts, P. Geusens, J. de Vries, P.P. Menheere, B.H. Wolffenbuttel, Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur. J. Endocrinol. 153, 23–29 (2005) CrossRef
33.
Zurück zum Zitat A.W. Kung, T. Lorentz, S.C. Tam, Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clin. Endocrinol. (Oxf.) 39, 535–540 (1993) CrossRef A.W. Kung, T. Lorentz, S.C. Tam, Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clin. Endocrinol. (Oxf.) 39, 535–540 (1993) CrossRef
Metadaten
Titel
Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study
verfasst von
Shiwei Wang
Yu Wang
Li Zhu
Liang He
Mutian Lv
Hao Zhang
Haoyu Wang
Fan Zhang
Yaxin Lai
Yushu Li
Zhongyan Shan
Weiping Teng
Publikationsdatum
12.09.2022
Verlag
Springer US
Erschienen in
Endocrine
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03186-6

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.